1
Home
Companies

Rubius Therapeutics

Rubius Therapeutics
Leadership team

Mr. Jose I. Carmona M.B.A. (Principal Accounting Officer & Treasurer)

Dr. Laurence A. Turka M.D. (Chief Scientific Officer and Head of Research & Translational Medicine)

Ms. Dannielle Appelhans (CEO & Pres)

Products/ Services
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2013
Company Registration
SEC CIK number: 0001709401
Traded as
RUBY
Social Media
URL
https://www.rubiustx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
History

Rubius Therapeutics was founded in 2018 by a team of accomplished scientists and innovators with a long history of creating breakthrough treatments for immune-mediated diseases. Our founders have a track record of developing successful therapies, including a major breakthrough in cancer immunotherapy and the creation of a novel therapeutic approach to treat all types of inflammatory conditions. We are focused on creating therapies that are tailored to the individual, and our goal is to deliver transformative treatments for patients suffering from autoimmune and inflammatory diseases.

Mission
At Rubius Therapeutics, our mission is to revolutionize the way immune-mediated diseases are treated. We are committed to advancing our world-class science to develop custom treatments tailored to each individual’s needs. Our ultimate goal is to improve the quality of life for patients around the world.
Vision
Rubius Therapeutics is committed to changing the landscape of medicine through innovation and creativity. Our vision is to create safe and effective therapies that are tailored to each individual’s needs, with the ultimate goal of improving the lives of millions of patients around the world.
Key Team

Ms. Marissa Hanify (Director of Corp. Communications)

Recognition and Awards
In 2019, Rubius Therapeutics was honored as a “breakthrough therapy” by the US Food and Drug Administration. We were also recognized as “Innovator of the Year” by BioPharma Magazine and “Start-up of the Year” by Pharmaceutical Executive Magazine.
References

https://in.investing.com/equities/rubius-therapeutics-inc

https://finance.yahoo.com/quote/RUBY/profile?p=RUBY

https://www.crunchbase.com/organization/rubius-therapeutics

https://companiesmarketcap.com/

https://www.rubiustx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Rubius Therapeutics
Leadership team

Mr. Jose I. Carmona M.B.A. (Principal Accounting Officer & Treasurer)

Dr. Laurence A. Turka M.D. (Chief Scientific Officer and Head of Research & Translational Medicine)

Ms. Dannielle Appelhans (CEO & Pres)

Products/ Services
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2013
Company Registration
SEC CIK number: 0001709401
Traded as
RUBY
Social Media
URL
https://www.rubiustx.com